Old drug shows new promise against Post-Surgery fluid buildup

NCT ID NCT02799212

Completed Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a 6-day infusion of somatostatin, a drug that lowers pressure in the liver's blood vessels, could prevent ascites (fluid buildup) after liver cancer surgery. 179 patients with liver cancer and underlying liver disease took part. The goal was to see if somatostatin reduces the need for drainage or punctures for fluid removal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: somatostatin
What this could lead to: If it works, this could offer a simple, temporary way to prevent dangerous fluid buildup after liver surgery, reducing complications and hospital stays.
What could go wrong: This is a completed Phase 3 trial, but results are not yet widely reported. The benefit may be modest or not apply to all patients, and somatostatin can cause side effects like nausea or blood sugar changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ascites hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

APHM - Hôpital de la Timone

Marseille, France
APHP - Hôpital Beaujon

Clichy, France
CHRU Lille - Hopital Huriez

Lille, France
CHU Rennes - Hôpital Pontchaillou

Rennes, France
CHU de Bordeaux - Hôpital Haut Lévèque

Pessac, France
CHU de Toulouse - Hopital Rangueil

Toulouse, France
Hospices Civils de Lyon - Hôpital de la Croix Rousse

Lyon, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.